35,130 Sofdra prescriptions as Botanix targets 50% cost reduction

Sofdra prescriptions grow while net revenue stalls

Botanix Pharmaceuticals Limited (ASX:BOT) increased Sofdra prescriptions shipped by 5.3% to 35,130 in Q1 FY27, even after reducing its US sales force from 50 to 39 professionals. The commercial traction is encouraging, but it did not translate into higher revenue: Sofdra net revenue remained at $10.1 million, while gross sales rose from $46.7 million to $49.3 million.

Botanix attributed the disconnect primarily to a lower average gross-to-net yield, which slipped to 21% from 22% in the previous quarter. The company said a temporary decline in prior authorisation submissions had been identified and addressed, with improvement expected in Q2 FY27 if other factors remain unchanged. Its own analysis points to potential gains from higher authorisation submission and approval rates, improved shipment rates, copay changes and greater patient persistence, though these are operating opportunities rather than reported outcomes.

The figures extend the commercial thread behind the company’s earlier Sofdra prescription growth, but the quarter also exposes the cost of converting prescriptions into cash. Operating cash outflow fell 13% to $9.225 million, helped by product sales receipts of $15.161 million and lower manufacturing costs, yet cash declined from $36.631 million to $24.358 million after debt repayments, interest and other financing movements.

Cost reset targets half the operating expense base

Botanix has since launched October cost actions estimated to reduce annual operating expenses by approximately 50% compared with Q1 FY27. The company said the measures produced a leaner US organisation, with corporate and sales headcount reduced by about 60%, while management models retain approximately 75% of revenue-generating ability. Those figures are management estimates, not a revenue forecast, and the central test will be whether the sales territories left standing can sustain Sofdra demand without weakening execution.

The cash calculation also needs careful handling. The 4C reports $14.332 million of unused finance facilities at quarter-end, producing a headline 4.19 quarters of funding based on the quarter’s operating cash outflow. However, availability under the relevant Kreos facility expired on 1 October 2026, after the quarter ended. Excluding that undrawn amount, Botanix said it had more than two quarters of cash reserves remaining.

API agreement and patent strengthen the Sofdra platform

Botanix has signed a commercial manufacturing and supply agreement with Piramal after six months of technical transfer work. The alternate API source is expected to reduce cost of goods sold by 25% to 40%, although the transfer must be completed before that benefit becomes an operating result. The agreement advances the Piramal alternate supply deal, which was previously described as a term-sheet arrangement aimed at diversifying supply and lowering costs.

A US patent covering the crystalline form and preparation method of Sofpironium Bromide, Sofdra’s active drug substance, was issued on 26 August and is expected to protect against unauthorised manufacturing through May 2040. Together with existing patents, Botanix said the new grant strengthens its intellectual property position and supports future commercialisation and partnering initiatives. The company also reported that inventory build-up ahead of US pharmaceutical tariffs created approximately $2 million of cash outflow in Q2 FY27, described as the only manufacturing cost projected for the rest of the financial year.

Board changes accompany a wider strategic review

Two Australian-resident non-executive directors, Stewart Washer and Danny Sharp, resigned on 17 October. Company Secretary Andrew Bickley and Australian CFO Graeme Morissey have filled the vacancies on an interim basis, although neither will be classified as independent because of their existing executive roles.

With its cash requirements being reset, Botanix says it is seeking revised debt terms, exploring complementary product acquisitions and in-licensing, considering out-licensing Sofdra outside the United States, and evaluating broader transactions, including opportunities to transact the company. No transaction has been announced. The next quarter should show whether the lower-cost structure can preserve prescription momentum while the gross-to-net recovery begins to appear in actual revenue and cash generation.